Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Cohort, Open-label Study to Evaluate the Pharmacokinetics of GSK2847065, the Metabolite of Retosiban (GSK221149) After Single and Repeat Oral Doses, the Pharmacokinetics of GSK221149 Coadministered With a High Fat Meal, and the Pharmacokinetics of GSK221149 Coadministered With an Inhibitor of CYP3A4 (Ketoconazole)

NCT01627587 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01627587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01627587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Cohort, Open-label Study to Evaluate the Pharmacokinetics of GSK2847065, the Metabolite of Retosiban (GSK221149) After Single and Repeat Oral Doses, the Pharmacokinetics of GSK221149 Coadministered With a High Fat Meal, and the Pharmacokinetics of GSK221149 Coadministered With an Inhibitor of CYP3A4 (Ketoconazole)
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
December 12, 2011
Completion date
February 9, 2012
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obstetric labour, premature